Arcticzymes
Enzyme supplier for molecular research, diagnostics and biomanufacturing, including cold-adapted and salt-active nucleases
Highlights
- New on EvolcAdded 2026-10-28
About Arcticzymes
ArcticZymes develops and supplies enzymes, including salt-active nucleases and other cold-adapted enzymes sourced from Arctic marine microorganisms (extremozymes). Its product range covers molecular tools, enzymes for molecular research and diagnostics, and GMP-grade nucleases for biomanufacturing.
The company sells to molecular research, diagnostics and biopharmaceutical customers, including developers of therapeutics, gene therapies and vaccines. It offers commercial supply of its enzymes and designs custom enzyme solutions for customers' specific conditions and processes.
ArcticZymes was founded in 2009 and is headquartered in Tromsø, Norway, where its labs are located, 350 km north of the Arctic Circle. Its product development, manufacturing, sales and marketing processes are certified to ISO 13485. The company states that it released the first commercially available salt-active nuclease in 2015. Michael B. Akoh has been CEO since September 2023.
Product: Enzymes, including salt-active nucleases and GMP-grade nucleases for biomanufacturing, plus molecular tools for research and diagnostics.
Jobs at Arcticzymes
Leadership
- Michael B. Akoh · CEOSource: company website
- Børge Sørvoll · CFOSource: company website
- Paul Blackburn · CCOSource: company website
More biotech & pharma companies
Artbio
Develops alpha radioligand cancer therapies for patients; lead prostate cancer candidate AB001 is in Phase 1 trialsNew on EvolcBenchmark Genetics Norway
Supplies salmon ova and genetics services to aquaculture producers worldwideNew on EvolcBio-Me
QPCR-based microbiome profiling for researchers, pharma and consumer health companies, with diagnostic test developmentNew on EvolcBionér
Soil and compost analysis services for farmers, compost producers and other land usersNew on EvolcBlue Analytics
Diagnostic and genomic lab analyses for fish health and aquaculture producers, run in Bergen, NorwayNew on EvolcCalluna Pharma
Clinical-stage biotech developing antibodies against fibrosis and inflammation, with lead asset CAL101 for IPFYoung companyNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- AWS
- Azure
- Cloudflare
- Google Ads
- Google Analytics 4
- Google Tag Manager
- Google reCAPTCHA
- Iubenda
- Stripe
- Webflow